Company
DermBiont
ADVANCING SM-030 FOR THE TREATMENT OF MELASMA AND HYPERPIGMENTATION DISORDERS OF THE SKIN
Also known as DermBiont, Inc.
- Status
- Operatingas of 2026-09-23
- Business model
- B2B
- Legal name
- DermBiont, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
DermBiont is advancing SM-030 for the treatment of melasma and hyperpigmentation disorders of the skin. The startup is advancing SM-030 to treat melasma and hyperpigmentation disorders of the skin.
Funding snapshot
- Total raised
- $114MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $32.7M2023-10-04
Funding rounds
- Round, 2023
- $32.7M2023-10-04, SEC form D sold, 81 investors
- Round, 2023
- $4.7M2023-03-06, SEC form D sold, 69 investors
- Round, 2022
- $2.5M2022-09-06, SEC form D sold, 11 investors
- Round, 2021
- $830K2021-12-30, SEC form D sold, 10 investors
- Round, 2021
- $28.8M2021-12-17, SEC form D sold, 42 investors
- Round, 2021
- $19.2M2021-08-04, SEC form D sold, 9 investors
- Round, 2021
- $6.6M2021-02-12, SEC form D sold, 19 investors
- Round, 2020
- $7.2M2020-10-16, SEC form D sold, 19 investors
- Round, 2020
- $2.9M2020-02-19, SEC form D sold, 14 investors
- Round, 2019
- $8.8M2019-05-31, SEC form D sold, 42 investors
Products
- Other
- SM-030
Loading relationship preview